Home
/
INOVIO PHARMACEUTICALS, INC.
/
Financials
/
Quarterly
INOVIO PHARMACEUTICALS, INC. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that INOVIO PHARMACEUTICALS, INC. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$1.53M
May 9, 2018
Q3
2017
Sep 30, 2017
$2.64M
Nov 8, 2017
Q2
2017
Jun 30, 2017
$20.41M
Aug 8, 2017
Q1
2018
Mar 31, 2017
$10.38M
May 9, 2018
Q3
2017
Sep 30, 2016
$12.54M
Nov 8, 2017
Q2
2017
Jun 30, 2016
$6.20M
Aug 8, 2017
Q1
2017
Mar 31, 2016
$8.11M
May 10, 2017
Q3
2016
Sep 30, 2015
$24.18M
Nov 9, 2016
Q2
2016
Jun 30, 2015
$5.29M
Aug 8, 2016
Q1
2016
Mar 31, 2015
$5.17M
May 9, 2016
Q3
2015
Sep 30, 2014
$1.84M
Nov 9, 2015
Q2
2015
Jun 30, 2014
$3.80M
Aug 10, 2015
Q1
2015
Mar 31, 2014
$2.36M
May 11, 2015
Q3
2014
Sep 30, 2013
$9.49M
Nov 10, 2014
Q2
2014
Jun 30, 2013
$785.6K
Aug 11, 2014
Q1
2014
Mar 31, 2013
$1.46M
May 12, 2014
Q3
2013
Sep 30, 2012
$854.7K
Nov 12, 2013
Q2
2013
Jun 30, 2012
$436.1K
Aug 9, 2013
Q1
2013
Mar 31, 2012
$1.69M
May 10, 2013
Q3
2012
Sep 30, 2011
$2.64M
Nov 7, 2012
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 10, 2025
Q2
2025
Jun 30, 2025
$0
Aug 12, 2025
Q1
2025
Mar 31, 2025
$65.3K
May 13, 2025
Q3
2025
Sep 30, 2024
$0
Nov 10, 2025
Q2
2025
Jun 30, 2024
$100.8K
Aug 12, 2025
Q1
2025
Mar 31, 2024
$0
May 13, 2025
Q3
2024
Sep 30, 2023
$388.4K
Nov 14, 2024
Q2
2024
Jun 30, 2023
$226.0K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$114.9K
May 13, 2024
Q3
2023
Sep 30, 2022
$9.15M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$784.4K
Aug 9, 2023
Q1
2023
Mar 31, 2022
$199.1K
May 10, 2023
Q3
2022
Sep 30, 2021
$291.7K
Nov 8, 2022
Q2
2022
Jun 30, 2021
$272.8K
Aug 9, 2022
Q1
2022
Mar 31, 2021
$371.1K
May 10, 2022
Q3
2021
Sep 30, 2020
$236.2K
Nov 9, 2021
Q2
2021
Jun 30, 2020
$267.2K
Aug 9, 2021
Q1
2021
Mar 31, 2020
$1.33M
May 10, 2021
Q3
2020
Sep 30, 2019
$866.9K
Nov 9, 2020
Q2
2020
Jun 30, 2019
$135.7K
Aug 10, 2020
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($45.50M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($23.52M)
Aug 12, 2025
Q3
2025
Jun 30, 2025
($23.52M)
Nov 10, 2025
Q2
2025
Mar 31, 2025
($19.69M)
Aug 12, 2025
Q3
2025
Mar 31, 2025
($19.69M)
Nov 10, 2025
Q1
2025
Mar 31, 2025
($19.69M)
May 13, 2025
Q3
2025
Sep 30, 2024
($25.17M)
Nov 10, 2025
Q3
2025
Jun 30, 2024
($32.24M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($32.24M)
Aug 12, 2025
Q3
2025
Mar 31, 2024
($30.47M)
Nov 10, 2025
Q2
2025
Mar 31, 2024
($30.47M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($30.47M)
May 13, 2025
Q3
2024
Sep 30, 2023
($33.93M)
Nov 14, 2024
Q3
2024
Jun 30, 2023
($35.53M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($35.53M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($40.65M)
May 13, 2024
Q2
2024
Mar 31, 2023
($40.65M)
Aug 8, 2024
Q3
2024
Mar 31, 2023
($40.65M)
Nov 14, 2024
Q3
2023
Sep 30, 2022
($37.78M)
Nov 9, 2023
Q3
2023
Jun 30, 2022
($108.50M)
Nov 9, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($21.21M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($23.08M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($25.05M)
May 13, 2025
Q3
2025
Sep 30, 2024
($27.35M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($33.20M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($31.48M)
May 13, 2025
Q3
2024
Sep 30, 2023
($35.55M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($37.04M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($43.95M)
May 13, 2024
Q3
2023
Sep 30, 2022
($35.76M)
Nov 9, 2023
Q2
2023
Jun 30, 2022
($104.14M)
Aug 9, 2023
Q1
2023
Mar 31, 2022
($71.73M)
May 10, 2023
Q3
2022
Sep 30, 2021
($59.95M)
Nov 8, 2022
Q2
2022
Jun 30, 2021
($83.20M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($52.55M)
May 10, 2022
Q3
2021
Sep 30, 2020
($36.33M)
Nov 9, 2021
Q2
2021
Jun 30, 2020
($33.18M)
Aug 9, 2021
Q1
2021
Mar 31, 2020
($25.23M)
May 10, 2021
Q3
2020
Sep 30, 2019
($23.95M)
Nov 9, 2020
Q2
2020
Jun 30, 2019
($28.20M)
Aug 10, 2020